Showing results (11-20 of 162) with videos related to
Sort By:
Pageof 17
The Lancet. Neurology|September 27, 2025
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applicationsTanuja Chitnis, Roberta Magliozzi, Ahmed Abdelhak, et al.Journal of Neuroinflammation|April 19, 2015
The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitisFabian D Liechti, Fabian Bächtold, Denis Grandgirard, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2021
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension studyHans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2020
Serum neurofilament light chains in MS: Association with the Timed Up and GoGilles Allali, Jens Kuhle, Gautier Breville, et al.Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|May 23, 2003
Respiratory failure due to bilateral diaphragm palsy as an early manifestation of ALSAdam Czapliński, Werner Strobel, Claudio Gobbi, et al.Neuropharmacology|January 14, 2014
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis modelDaniel C Anthony, Nicola R Sibson, Patrick Losey, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 3, 2021
Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple SclerosisJay Roodselaar, Yifan Zhou, David Leppert, et al.Journal of Neuroinflammation|October 8, 2020
Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitisNgoc Dung Le, Lukas Muri, Denis Grandgirard, et al.Multiple Sclerosis and Related Disorders|February 8, 2021
Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTIMaija Saraste, Svetlana Bezukladova, Markus Matilainen, et al.BMJ Open|January 12, 2021
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progressionSteve Vucic, Matthew C Kiernan, Parvathi Menon, et al.Pageof 17